Stock RMDA TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) S.A.E.
Add to a list
To use this feature you must be a member
Log inSign up

Company Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Equities

RMDA

EGS381B1C015

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 06:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
2.07 EGP +0.49% Intraday chart for Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. -6.76% +25.45%
Mar. 19 Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Business Summary

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents S.A.E (RAMEDA) specializes in the manufacture and marketing of generic pharmaceutical products. The products include antibiotics, vitamins, analgesics, medicines for ophthalmological care, gastrointestinal, dermatological and cardiovascular diseases, food supplements, medical devices and veterinary products.

Sales per Business

EGP in Million2021Weight2022Weight Delta
Pharmaceutical Products
91.1 %
1,169 93.8 % 1,352 91.1 % +15.62%
Toll Manufacturing Services
8.9 %
77 6.2 % 132 8.9 % +70.91%

Sales per region

EGP in Million2021Weight2022Weight Delta
Egypt
100.0 %
1,246 100.0 % 1,484 100.0 % +19.06%

Managers

Managers TitleAgeSince
Amr Morsy CEO
 Chief Executive Officer - 10-12-31
Mahmoud Fayek DFI
 Director of Finance/CFO - 18-12-31
Rania Farouk CTO
 Chief Tech/Sci/R&D Officer - -
Osama Hussein CTO
 Chief Tech/Sci/R&D Officer - 20-12-31
Ehab Adel CMP
 Compliance Officer - -
Khaled Abdel Hamid IRO
 Public Communications Contact - -
Aboamira Mohamed IRC
 Investor Relations Contact - -
Najla Muttawa HRO
 Human Resources Officer - -
Amgad El Gabri PRN
 Corporate Officer/Principal - -
Hussein Azmy PRN
 Corporate Officer/Principal - 11-12-31

Members of the board

Members of the board TitleAgeSince
Farida Khamis BRD
 Director/Board Member - 19-12-31
Hatem Al Sayed Soliman BRD
 Director/Board Member 65 18-12-31
Shamel Aboul Fadl BRD
 Director/Board Member - 10-12-31
Tarek Abdel Rahman BRD
 Director/Board Member - -
Mohamed Abdelkhalek BRD
 Director/Board Member 55 15-12-31
Ayman Abbas CHM
 Chairman 49 10-12-31
Karim Zahran BRD
 Director/Board Member 39 17-12-31
Amr Morsy CEO
 Chief Executive Officer - 10-12-31
Mahmoud Fayek DFI
 Director of Finance/CFO - 18-12-31
Mohamed Gamal El Shoura BRD
 Director/Board Member - 21-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,500,000,000 754,177,181 ( 50.28 %) 9,470,000 ( 0.6313 %) 50.28 %

Shareholders

NameEquities%Valuation
Aquinox Pharma Holding Ltd.
12.96 %
196,962,174 12.96 % 11 M £
Sadik Mohammed Afifi Sadik
7.897 %
120,032,754 7.897 % 7 M £
Atlantica Holdings, Inc.
6.963 %
105,830,772 6.963 % 6 M £
Infinity Capital Investments Ltd.
6.164 %
93,688,610 6.164 % 5 M £
Old Mutual Investment Group (Pty) Ltd.
2.057 %
31,267,544 2.057 % 2 M £
Sanlam Investment Management (Pty) Ltd.
1.152 %
17,509,107 1.152 % 997 319 £
Silk Invest Ltd.
0.2487 %
3,779,586 0.2487 % 215 285 £
Rudiarius Capital Management (Pty) Ltd.
0.1356 %
2,060,663 0.1356 % 117 375 £
Mashreq Capital DIFC Ltd. (Investment Management)
0.1249 %
1,897,812 0.1249 % 108 099 £

Company contact information

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda

Second Industrial Zone Plot No. 5

00001, 6th of October City

+20 2 3820 2766

http://www.ramedapharma.com
address Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.(RMDA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Ratings for Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.07 EGP
Average target price
3.472 EGP
Spread / Average Target
+67.71%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) S.A.E. Stock Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.
+25.45% 64.35M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 325B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
NOVARTIS AG Stock Novartis AG
+3.65% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RMDA Stock
  4. Company Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.